Launched in 2013, the Preeclampsia Registry was built to create a partnership between preeclampsia survivors and researchers to advance our understanding of preeclampsia. As participants share their experiences, approved researchers are provided with access to “de-identified” health information – information that does not contain participant names or contact information. This helps researchers to find patterns that can lead to findings and further studies. The registry also accelerates studies as researchers are able to gather cohorts for new studies or pose new questions.
The Preeclampsia Registry also gives its participants the option of learning about other research studies for which they may qualify and provides them with the means of connecting with researchers.
Most importantly, patient registries unite the patient voice with research. Patients have questions, theories, and interests that are often different from investigators conducting formal research. By engaging patients in the research process, as we can through patient registries, the chances for discovery and improvement are an even greater possibility.
Have questions? Contact Research Manager Marne Silk at registry@preeclampsia.org.
The Preeclampsia Registry Advisory Council (PRAC) played a key role in the development of the Preeclampsia Registry and continues to be essential to its integrity. The PRAC provides representation amongst many disciplines including epidemiology, internal medicine, pediatrics, nephrology, genomics, obstetrics and gynecology (including Maternal Fetal Medicine), industry, National Institutes of Health, Centers for Disease Control, patient/consumer, and the Preeclampsia Foundation Medical Medical Advisory Board.
Jim Roberts, MD
Co-Chair
University of Pittsburgh
Magee Women's Research Institute
Sarosh Rana, MD
Co-Chair
University of Chicago
Eleni Tsigas, BA
Preeclampsia Foundation, Chief Executive Officer
Principal Investigator, Preeclampsia Registry
Arun Jeyabalan, MD
University of Pittsburgh
Michelle Owens, MD
University of Mississippi
Janet Rich-Edwards, ScD
Harvard Medical School
Ellen Seely, MD
Brigham and Women's Hospital
Ananth Karumanchi, MD
Howard Hughes Research Institute
Harvard Medical School
Terry Morgan, MD, PhD
Oregon Health Sciences University
Alison Roberts, CNM
West Berkeley Family Practice
Kent Thornburg, PhD
Oregon Health and Science University
Tom Easterling, MD
University of Washington
Kyu-Ho Lee, MD PhD
Medical University of South Carolina
Robert Powers, PhD
University of Pittsburgh
Donna Russell, MHA
Precia Group
Kenneth Ward, MD
Juneau Biosciences
Marne Silk (ex-officio)
Preeclampsia Foundation, Registry Manager
I have had two very different experiences with Preeclampsia.
My first in 2019, with our first daughter Sophia. My pregn...
ReadMorePlease contact our Research Manager if you would like the Preeclampsia Foundation to help you recruit participants for a research study or focus group, or have any questions about the Preeclampsia Registry.
Your story is needed to improve outcomes for moms like you. Add your voice to critical preeclampsia research to ensure that every story is heard.
Frequently asked questions about the Preeclampsia Registry, a patient-driven registry and biobank.
The Preeclampsia Foundation offers research funding, study recruitment, and other patient engagement services to researchers.
We provide research grant funding to advance progress towards detection, prevention, or treatment of preeclampsia, HELLP syndrome, and other hypertensive disorders of pregnancy.
May 19, 2023 – NEW YORK – Thermo Fisher Scientific announced on Friday, May 19 that it has obtained clearance from the US Food and Drug Administration for two assays to assess risk of...
A new research study published out of the UK in April 2023 in Hypertension found that more than half of all preeclampsia cases which occur during weeks 37-42 of pregnancy (“at-term”) may b...
Long-term neurodevelopmental follow-up of children exposed to pravastatin in utero If given in early pregnancy pravastatin, (a drug used to lower cholesterol) may decrease the risk of developing pree...
Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy (a rat model) Currently the only treatment for preeclampsia starts with delivery of the baby and the placenta....
The nuMom2b study – short for “Nulliparous* Pregnancy Outcomes Study: Monitoring Mothers-To-Be” – is a prospective study that enrolled over 10,000 first time pregnant women acr...